Oncology Institute Inc (TOI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncology Institute Inc (TOI) has a cash flow conversion efficiency ratio of 0.136x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.21 Million) by net assets ($-16.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TOI equity to assets ratio to measure how much of total assets are equity-financed.
Oncology Institute Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Oncology Institute Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Oncology Institute Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Oncology Institute Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncology Institute Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
|
0.021x |
|
Jerusalem
TA:JBNK
|
0.033x |
|
Fujian Minfa Aluminium Co Ltd
SHE:002578
|
-0.035x |
|
Freegold Ventures Limited
TO:FVL
|
-0.001x |
|
International Money Express Inc
NASDAQ:IMXI
|
-0.123x |
|
Grand Korea Leisure Co. Ltd
KO:114090
|
0.012x |
|
Malaysia Smelting Corporation Bhd
KLSE:5916
|
0.133x |
|
Einhell Germany AG
F:EIN
|
0.049x |
Annual Cash Flow Conversion Efficiency for Oncology Institute Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Oncology Institute Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see TOI market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-15.72 Million | $-24.59 Million | 1.564x | +121.15% |
| 2024-12-31 | $3.59 Million | $-26.54 Million | -7.394x | -1061.11% |
| 2023-12-31 | $57.02 Million | $-36.31 Million | -0.637x | -27.02% |
| 2022-12-31 | $123.17 Million | $-61.76 Million | -0.501x | -59.80% |
| 2021-12-31 | $104.16 Million | $-32.68 Million | -0.314x | -1835.57% |
| 2020-12-31 | $28.10 Million | $508.00K | 0.018x | -78.89% |
| 2019-12-31 | $42.22 Million | $3.62 Million | 0.086x | -- |
About Oncology Institute Inc
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as edu… Read more